Immunoediting and persistence of antigen-specific immunity in patients who have previously been vaccinated with NY-ESO-1 protein formulated in ISCOMATRIX™.
Nicholaou T, Chen W, Davis ID, Jackson HM, Dimopoulos N, Barrow C, Browning J, Macgregor D, Williams D, Hopkins W, Maraskovsky E, Venhaus R, Pan L, Hoffman EW, Old LJ, Cebon J.
Nicholaou T, et al. Among authors: cebon j.
Cancer Immunol Immunother. 2011 Nov;60(11):1625-37. doi: 10.1007/s00262-011-1041-3. Epub 2011 Jun 23.
Cancer Immunol Immunother. 2011.
PMID: 21698545
Free PMC article.
Clinical Trial.